Personal Genome Diagnostics Inc., a Baltimore, MD-based provider of advanced cancer genome analyses, raised $2.8m in its first external financing.
Backers included several undisclosed private investors.
The new funds will be used to help support further development and marketing of the company’s circulating tumor DNA assays.
Founded in 2010 by Luis Diaz, MD, and Victor Velculescu, MD, PhD, Personal Genome Diagnostics provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its expertise in cancer biology to identify and characterize genomic alterations in tumors.
Since its inception, Personal Genome Diagnostics has been funded by revenues from the cancer genome analysis services it provides to a wide variety of biopharmaceutical firms, academic research centers, contract research organizations and cancer patients and physicians.